Metabolism Comparative Cytotoxicity Assay (MCCA) and Cytotoxic Metabolic Pathway Identification Assay (CMPIA) with cryopreserved human hepatocytes for the evaluation of metabolism-based cytotoxicity in vitro: Proof-of-concept study with aflatoxin B1

Chemico-Biological Interactions

Volumn 179, Issue 1, 2009, Pages 4-8

  Li, Albert P ^a  

^a In Vitro ADMET Laboratories LLC   (United States)

Author keywords

1 Aminobenzotrizole; Aflatoxin B1; Cryopreservation; Drug metabolism; Drug toxicity; Human hepatocytes; In vitro toxicity; P450 inhibitors; P450 isoforms

Indexed keywords

1 AMINOBENZOTRIAZOLE; AFLATOXIN B1; CYTOCHROME P450 ISOENZYME; DIETHYLDITHIOCARBAMIC ACID; FURAFYLLINE; KETOCONAZOLE; QUINIDINE; SULFAPHENAZOLE;

ADULT; ANIMAL CELL; ARTICLE; CELL TYPE; CHO CELL; CONTROLLED STUDY; CRYOPRESERVATION; CYTOTOXIC METABOLIC PATHWAY IDENTIFICATION ASSAY; CYTOTOXICITY; DRUG TRANSFORMATION; ENZYME ANALYSIS; HUMAN; HUMAN CELL; LIVER TOXICITY; MALE; METABOLIC ACTIVATION; METABOLISM COMPARATIVE CYTOTOXICITY ASSAY; NONHUMAN; TOXICITY TESTING; TOXICOKINETICS; XENOBIOTIC METABOLISM;

AFLATOXIN B1; ANIMALS; CHO CELLS; CRICETINAE; CRICETULUS; CRYOPRESERVATION; CYTOCHROME P-450 ENZYME SYSTEM; DRUG EVALUATION, PRECLINICAL; HEPATOCYTES; HUMANS; ISOENZYMES;

CRICETULUS GRISEUS;

EID: 59649093477     PISSN: 00092797     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cbi.2008.09.026     Document Type: Article

References (15)

1. Schachter A.D., and Ramoni M.F. Clinical forecasting in drug development. Nat. Rev. Drug Discov. 6 (2007) 107-108
2. Li A.P. A comprehensive approach for drug safety assessment. Chem. Biol. Interact. 150 (2004) 27-33
3. Hewitt P., and Walijew A. Toxicogenomics in drug safety assessment. Pharmacogenomics 9 (2008) 379-382
4. Li A.P. A review of the common properties of drugs with idiosyncratic hepatotoxicity and the "multiple determinant hypothesis" for the manifestation of idiosyncratic drug toxicity. Chem. Biol. Interact. 142 (2002) 7-23
5. Li A.P. Human hepatocytes: isolation, cryopreservation and applications in drug development. Chem. Biol. Interact. 168 (2007) 16-29
6. FDA, Drug Interaction Studies - Study Design, Data Analysis, and Implications for Dosing and Labeling, FDA, 2006. http://www.fda.gov/cder/guidance/6695dft.htm.
7. Ortiz de Montellano P.R., Mathews J.M., and Langry K.C. Autocatalytic inactivation of cytochrome P-450 and chloroperoxidase by 1-aminobenzotriazole and other aryne precursors. Tetrahedron 40 (1984) 511-519
8. Emoto C., Murase S., Sawada Y., and Iwasaki K. In vitro inhibitory effect of 1-aminobenzotriazole on drug oxidations in human liver microsomes: a comparison with SKF-525A. Drug Metab. Pharmacokinet. 20 (2005) 351-357
9. Shimada T., and Guengerich F.P. Evidence for cytochrome P-450NF, the nifedipine oxidase, being the principal enzyme involved in the bioactivation of aflatoxins in human liver. Proc. Natl. Acad. Sci. U.S.A. 86 (1989) 265-462
10. Baertschi S.W., Raney K.D., Shimada T., Harris T.M., and Guengerich F.P. Comparison of rates of enzymatic oxidation of aflatoxin B1, aflatoxin G1, and sterigmatocystin and activities of the epoxides in forming guanyl-N7 adducts and inducing different genetic responses. Chem. Res. Toxicol. 2 (1989) 114-122
11. Guengerich F.P., Johnson W.W., Ueng Y.F., Yamazaki H., and T. Shimada. Involvement of cytochrome P450, glutathione S-transferase, and epoxide hydrolase in the metabolism of aflatoxin B1 and relevance to risk of human liver cancer. Environ. Health Persp. 104 (1996) 557-562
12. Gonzalez F.J., Crespi C.L., Czerwinski M., and Gelboin H.V. Analysis of human cytochrome P450 catalytic activities and expression. Tohoku J. Exp. Med. 168 (1992) 67-72
13. MacGregor J.T., Collins J.M., Sugiyama Y., Tyson C.A., Dean J., Smith L., Andersen M., Curren R.D., Houston J.B., Kadlubar F.F., Kedderis G.L., Krishnan K., Li A.P., Parchment R.E., Thummel K., Tomaszewski J.E., Ulrich R., Vickers A.E., and Wrighton S.A. In vitro human tissue models in risk assessment: report of a consensus-building workshop. Toxicol. Sci. 59 (2001) 17-36
14. Li A.P. Screening for human ADME/Tox drug properties in drug discovery. Drug Discov. Today 6 (2002) 357-366
15. Li A.P., Lu C., Brent J.A., Pham C., Fackett A., Ruegg C.E., and Silber P.M. Cryopreserved human hepatocytes: characterization of drug-metabolizing enzyme activities and applications in higher throughput screening assays for hepatotoxicity, metabolic stability, and drug-drug interaction potential. Chem. Biol. Interact. 121 (1999) 17-35